Patent · US Active

Glycoengineered antibody drug conjugates

US11160874B2 · kind B2 · utility

4Cited by

37References

15Claims

0Family size

Assignee

Genzyme Corporation · US

Inventors

Luis Z. Avila · Arlington, US
Qun Zhou · Ashland, US

Key dates

Filing date	Aug 6, 2018
Grant date	Nov 2, 2021
Priority date	—
Expiry date	Dec 9, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.